Increasing development costs and rapid advancements in science and technology are compelling drug development, medical device and diagnostic companies to evaluate resource-sharing business models. For many, creating a partnership with an academic medical center is the solution for reducing product development costs, keeping pace with an ever-changing regulatory environment and capitalizing on the latest research discoveries and technology breakthroughs.
Academic medical centers have a translational research culture that offers a breadth of basic science, clinical and diagnostic capabilities. This culture unites leading scientists with expertise in every phase of the product development continuum in a setting that fosters accelerated and innovative solutions. These qualities make academic institutions attractive partners for private companies: More than 20 notable pharma-academic alliances were formed in 2012, and the number continues to grow.
This webinar will discuss the benefits of partnering with an academic medical center and will feature case studies for successful biomarker discovery, biomarker development and companion diagnostics co-development.
Steve Groshong, MD, PhD, Pathology Division Chief, National Jewish Health
Dr. Groshong is board certified in anatomic and clinical pathology and has led the Division of Pathology at National Jewish Health since 2006. He currently serves as the president of the National Jewish Health Medical Executive Committee and is an associate professor in Medicine at National Jewish Health and the University of Colorado Denver .
Dr. Groshong was instrumental in developing the biorepository and research database, two essential components of the translational research environment at National Jewish Health. He is well-versed on International Research Board and Honest Broker regulatory compliance. He has a PhD in biophysics and genetics and has more than 35 publications in basic, translational and clinical research.
Dr. Groshong completed an internship in Translational Medicine from Presbyterian/St. Luke’s Hospital in Denver, residency in Clinical and Anatomic Pathology and fellowship in surgical pathology from the University of Colorado Health Sciences Center.Message Presenter
Preveen Ramamoorthy, PhD, Molecular Diagnostics Laboratory Director, National Jewish Health
Dr. Ramamoorthy founded the Molecular Diagnostics department at National Jewish Health in 2007. Currently, he directs the translation of genomic biomarkers into molecular diagnostic tests at National Jewish Health Advanced Diagnostic Laboratories.
Prior to joining National Jewish Health, Dr. Ramamoorthy developed viral vaccines, cancer vaccines and monoclonal antibodies at MedImmune (Astra Zeneca company).
Dr. Ramamoorthy completed his post-doctoral fellowship at Walter Reed Army Institute of Research in genomics and molecular diagnostics. He also holds a master’s degree in medical microbiology and has a PhD in microbiology.
Dr. Ramamoorthy co-invented a prolactin receptor antagonist, a molecular therapeutic drug for breast cancer and co-founded the Q-PCR symposium USA in 2007. He serves on the scientific advisory board of PrognosDx, TATAA Biocenter, Genome International Corporation, Global Chest Initiatives and International Asthma Services.Message Presenter
Who Should Attend?
Professionals from pharmaceutical, biotechnology, life sciences and diagnostic companies with responsibilities and interests in the following areas:
- Clinical Operations
- Clinical Quality Assurance
- Clinical Research
- Clinical Trial Capacity Planning/Management
- Clinical Trial Process Improvement/Enhancement
- Project Planning
- Strategic Development
National Jewish Health
National Jewish Health is known worldwide for treatment of patients with respiratory, cardiac, immune and related disorders, and for groundbreaking medical research. U.S. News & World Report has ranked National Jewish Health the #1 respiratory hospital in the United States for the past 15 consecutive years. With a focus on preventive and personalized medicine, our internationally recognized physicians and scientists work together to transform patient care from reactive to proactive by integrating our research, diagnostic and clinical care efforts for the patient.